TPD & Induced Proximity Summit Leaderboard
  • Sunday, June 21, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 40

Author

Pharma Journalist 8887 posts 0 comments

Lotus Files South Korea NDA for LENZ’s Presbyopia Drug VIZZ

Dec 2, 2025
LENZ Therapeutics and Lotus Pharmaceutical have reached a key regulatory milestone with the submission of a New Drug Application (NDA) to South Korea’s Ministry of Food and Drug Safety…
Read More...

FDA Grants Rare Pediatric Disease Status to Solid Biosciences’ FA Therapy

Dec 2, 2025
Solid Biosciences Inc. has received a significant regulatory boost as the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to SGT-212, the…
Read More...

Final Days to Save £200 on AI in Drug Discovery 2026 Registration – Offer Ends 5 December

Nov 26, 2025
London, UK – The countdown is on for the 7th Annual AI in Drug Discovery Conference, taking place 9th-10th March 2026 in London. Delegates have until 5th December to secure a £200…
Read More...

Telix Opens First APAC Radiopharmaceutical Manufacturing Site in Japan

Nov 25, 2025
Telix Pharmaceuticals has officially opened its first cyclotron-equipped manufacturing facility in the Asia-Pacific region, marking a significant expansion of the company’s…
Read More...

Made Scientific, Cellergy Partner to Advance First Mitochondrial Therapy

Nov 25, 2025
Made Scientific, Inc., a U.S.-based clinical and commercial-stage cell therapy contract development and manufacturing organization (CDMO), has announced a new manufacturing partnership…
Read More...

Novo Nordisk Alzheimer’s Trials Show No Benefit for Semaglutide

Nov 25, 2025
Novo Nordisk has reported top-line findings from its two major phase 3 Alzheimer’s disease trials, evoke and evoke+, revealing that oral semaglutide did not demonstrate superiority to…
Read More...

FDA Approves First Gene Therapy for Broad SMA Patient Population

Nov 25, 2025
The U.S. Food and Drug Administration (FDA) has approved Novartis’ Itvisma® (onasemnogene abeparvovec-brve) for children aged two years and older, as well as teens and adults, living…
Read More...

Vaximm Enters Talks for Global License of Oral Cancer Therapy

Nov 24, 2025
OSR Holdings, Inc. announced that its subsidiary Vaximm AG has signed a non-binding term sheet with Swiss-based life sciences investment group BCM Europe AG (BCME) to evaluate a…
Read More...

AstraZeneca to Invest $2 Billion in Major Maryland Expansion

Nov 24, 2025
AstraZeneca announced plans to invest $2 billion to significantly expand its manufacturing presence in Maryland, marking one of the company’s largest U.S. investments to date. The…
Read More...

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to $2.37 Billion

Nov 21, 2025
Alkermes plc and Avadel Pharmaceuticals have agreed to revised terms for Alkermes’ acquisition of Avadel, increasing the total potential value of the deal to $22.50 per share. The new…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.